Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 467 of 5804
-
Blowing away breast cancer: a breath test could spot the disease early
Diagnosis Recruiting nowResearchers will compare the breath profiles of women with breast cancer and those without to determine whether there are disease-specific patterns that can be leveraged to facilitate breast cancer detection. Women with mammogram-confirmed breast tissue density undergoing standa…
Sponsor: Breathe BioMedical Inc • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New triplet therapy hopes to shrink liver tumors
Disease control Recruiting nowThe purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Phase: PHASE2 • Sponsor: Inova Health Care Services • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Supercharged immune cells take on hard-to-treat melanoma in early trial
Disease control Recruiting nowTo find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThe study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced/metastatic solid tumors
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New cocktail of drugs targets Hard-to-Treat stomach cancer
Disease control Recruiting nowIn this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could umbilical cord stem cells repair damaged livers?
Disease control Recruiting nowPhase I (Single Administration, Randomized, Double-blind, Dose Escalation)Primary Objective: To evaluate the safety and tolerability of Human Umbilical Cord Mesenchymal Stem Cell Injection in patients with decompensated hepatitis B cirrhosis, and to determine the safe clinical do…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tuohua Weiye Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Promising cocktail targets tough lung cancer
Disease control Recruiting nowTo explore the efficacy and safety of Tislelizumab combined with chemotherapy and relayed radiotherapy in the first-line treatment of extensive small cell lung cancer
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Triple-Action antibody takes on advanced cancers
Disease control Recruiting nowThis is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The stud…
Phase: PHASE1, PHASE2 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo aims to control bladder cancer when standard therapy fails
Disease control Recruiting nowThis is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC. Arm A will enroll 43 participants who have cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will enroll 17 pa…
Phase: PHASE2 • Sponsor: John Sfakianos • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Bronx lung cancer screening overhaul aims to catch tumors early
Prevention Recruiting nowThis study proposes to increase Lung-cancer screening (LCS) in the Bronx, New York. Despite strong evidence that Lung-cancer screening (LCS) can reduce Lung cancer (LCa) deaths, low-dose computed tomography (LDCT) referral rates by clinicians are very low and there is poor adhere…
Phase: NA • Sponsor: Albert Einstein College of Medicine • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Pregnancy vaccine shields babies from RSV? new study investigates
⭐️ VACCINE ⭐️ OngoingGlobally, respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease (LRTD) in infants and children. Pfizer has developed ABRYSVO-a bivalent RSV prefusion F protein-based vaccine (RSVpreF) composed of two prefusion F proteins to protect against both…
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
New drug cocktail targets tough colorectal cancers
Disease control Recruiting nowTo learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cell therapy YTB323 targets MS that breaks through strongest drugs
Disease control Recruiting nowThis is an open-label, multi-center, non-confirmatory study to assess the safety, efficacy, and cellular kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity during previous treatment with a highly efficaci…
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New mRNA vaccine targets brain infection in global trial
⭐️ VACCINE ⭐️ Recruiting nowThis is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
Phase: PHASE1, PHASE2 • Sponsor: SK Bioscience Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:06 UTC
-
Blood test may predict immunotherapy success in lung cancer
Diagnosis Recruiting nowThis is a prospective, non-interventional, national study planned at three centers for patients with non-curative NSCLC receiving immunotherapy. At present, PD-L1 expression or tumor mutation burden serve as surrogate parameters for response to immunotherapy. However, the proble…
Sponsor: Karsten Gavenis • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
Extra radiation boost shows promise for bulky cervical cancer
Disease control Recruiting nowThe goal of this clinical trial is to learn if adding a radiation boost (intra-lesional boost) works to treat patients with large-sized cervical cancer. It will also learn about the safety of this treatment. The main questions it aims to answer are: * Does the extra radiation bo…
Phase: PHASE2 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for rare blood cancer: targeted drug plus chemotherapy under study
Disease control Recruiting nowTo learn if the study drug golidocitinib given alone or in combination with the standard drug combination therapy called CHOP can help to control PTCL.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Sound sleep: new device aims to boost brain health with targeted tones
Symptom relief Recruiting nowThis study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality. Dementia, a leading cause of death worldwide, is often associated with disturbed sleep, particularly the loss of deep, slow-wave sleep (SWS). SWS…
Phase: NA • Sponsor: University of Bern • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
New lung cancer combo aims to shrink tumors before surgery
Disease control Recruiting nowThe goal of this clinical trial is to learn if Cemiplimab with chemotherapy or Cemiplimab with stereotactic body radiation therapy (SBRT) works as treatment for stages IB, II, and III (N2) Non-Small Cell Lung Cancer (NSCLC). Before surgery to remove their lung cancer, participan…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill could ease joint pain for psoriatic arthritis patients
Disease control OngoingThe purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC